A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

• Status: Completed
• Trial end date: 2017-10-13
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Foamix Ltd.; Vyne Therapeutics Inc.
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Has facial acne vulgaris with:

• 20 to 50 inflammatory lesions (papules, pustules, and nodules);

• 25 to 100 noninflammatory lesions (open and closed comedones);

• no more than 2 nodules on the face; and

• IGA score of moderate (3) to severe (4)

• Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study

Exclusion Criteria:

• Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne) or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations

• Sunburn on the face

• Severe systemic disease, which might interfere with the conduct of the study or the interpretation of the results.

• Abnormal baseline laboratory values that are considered clinically significant

• Allergy to tetracycline-class antibiotics or to any ingredient in the study drug

• Pseudomembranous colitis or antibiotic-associated colitis